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Signal transducers and activators of transcription (STAT)
proteins nuclear translocation and transcriptional activity
are regulated by diverse protein kinases in response to
extracellular stimuli by cytokines, growth factors and
stress. Using two melanoma-derived cell lines that exhibit
marked differences in basal activities of MAPKs and
PI3K-AKT, we studied changes both in STAT activities
and in their sensitization to apoptosis. Activating muta-
tions of B-RAF (T1796A) and impaired expression of
PTEN are detected in LU1205, but not in FEMX
melanoma cells, and are reflected in high basal levels of
expression and activities of MAPKs and PI3K-AKT.
Treatment with either PD98059 (PD) or LY294002 (LY),
the pharmacological inhibitors of MEK-ERK and PI3K,
respectively, markedly increased GAS-Luc activity in
LU1205, but not in FEMX cells. Tyrosine phosphoryla-
tion of STAT3/5 and of JAK2 also increased upon
treatment of LU1205 cells with either PD or LY,
suggesting that constitutive active MAPK and PI3K
signals inhibit tyrosine phosphorylation of JAK/STATs.
Treatment of FEMX and LU1205 with PD sensitized the
cells to apoptosis, albeit by TNFa and TRAIL death
cascades, respectively, indicating that additional yet
distinct targets are affected by each signaling pathway.
Indeed, the combination of LY and PD treatment
synergistically increased the apoptosis of LU1205 and
FEMX cells. Overall, whereas PI3K and MAPK down-
regulate JAK-STAT signaling, additional targets are
affected by these kinases and sensitizes melanoma to
apoptosis via distinct death cascades.
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Introduction
Signal transducers and activators of transcription
(STAT) proteins are dual function molecules that can
be activated by diverse extracellular stimuli to transmit
signals from the cell surface to the nucleus and directly
participate in gene regulation (Ihle, 1995; Darnell, 1997).
Activation of STATs results in expression of genes that
control critical cellular functions (reviewed in Bowman
et al., 2000; Bromberg and Darnell, 2000). Ligand-
dependent activation of STATs is often associated with
differentiation and/or growth regulation, whereas con-
stitutive activation is often associated with growth
disregulation. An increasing number of tumor-derived
cell lines as well as samples from human cancers are
reported to contain constitutively activated STAT
proteins that are, in most cases, STAT3 and STAT5
(Gouilleux-Gruart et al., 1996; Weber-Nordt et al.,
1996; Chai et al., 1997; Garcia et al., 1997; Garcia and
Jove, 1998; Grandis et al., 2000; Levy and Gilliland,
2000). Abundant evidence strongly suggests that aber-
rant STAT3 signaling is an important process in
malignant progression, but the regulation of STAT3
during tumorigenesis is not well understood.
The prerequisite for STAT transcriptional activities
lies in its phosphorylation. Phosphorylation of STAT3
on Tyr 705 is mediated by Janus Kinases (JAKs;
Darnell, 1997) and Rac1 (Simon et al., 2000), and
results in its homo- or heterodimerization which enables
nuclear localization and DNA binding (Darnell, 1997).
Phosphorylation on Ser 727 alters its transcriptional
activities (Wen et al., 1995; Wen and Darnell 1997) and
is mediated by the serine threonine kinases including
MAPK, JNK and p38 (Chung et al., 1997; Sengupta
et al., 1998; Lim and Cao, 1999). Evidence is accumulat-
ing in support of PI3K’s role in tyrosine phosphoryla-
tion of STATs (Sharfe et al., 1995; Yamauchi et al.,
1998), possibly via members of the Src tyrosine kinase
family that link cytokine receptors to PI-3 kinase
through JAK (Takahashi-Tezuka et al., 1997).
Several mechanisms that inhibit JAK-STAT signaling
have been described. They include dephosphorylation,
proteolytic degradation, or association with inhibitory
molecules (Haspel et al., 1996; Kim and Maniatis 1996;
Shuai et al., 1996; Azam et al., 1997; Chung et al., 1997;
Sengupta et al., 1998). Activation of PKC or PKA, for
example, inhibits JAK-STAT signaling through me-
chanisms that are not completely understood (Sengupta
et al., 1996). Members of the MAPK family, including
ERK, elicited both positive and negative effects on
JAK-STAT signaling (David et al., 1995; Fukada et al.,
1996; Minami et al., 1996; Bonni et al., 1997; Czerniecki
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et al., 1997; Ihara et al., 1997; Boccaccio et al., 1998).
The mechanisms underlying inhibition of STAT activ-
ities include both serine and tyrosine phosphorylation.
Evidence in support of the possible effect of ERK on
JAK activities is accumulating (Sengupta et al., 1998).
In earlier studies, we demonstrated that STAT
cooperation with c-Jun results in silencing Fas receptor
expression in advanced humanmelanomas (Ivanov et al.,
2001). Further, we showed that PI3K-PKB elicits signals
that inhibit both STAT3 and c-Jun transcriptional
activities, which attenuates their inhibition of Fas
promoter and results in concomitant upregulation of
Fas receptor expression (Ivanov et al., 2002). Advanced
melanoma often overrides PI3K because MAPK is
constitutively active. In all, 15–25% of melanomas are
mutated within the Ras oncogene, and B-RAF muta-
tions were reported to occur at a high frequency
(460%) in primary melanoma samples and in corre-
sponding cell lines (Brose et al., 2002; Davies et al.,
2002). Together these mutations occur in about 80% of
melanomas that exhibit high levels of MAPK activities.
In addition, PI3K activities are also upregulated as a
result of impaired PTEN expression. Since both PI3K
and MAPK appear to play a central role in the
regulation of STAT activities and consequently in the
sensitivity of melanoma to apoptosis, we assessed
possible changes in STAT transcriptional activities using
melanoma cells that harbor constitutively active MAPK
versus cells that do not. Here we demonstrate that ERK
and PI3K both negatively regulate the transcriptional
activities of STATs and establish new links between
these signaling cascades, the regulation of STATs and
sensitization to apoptosis in melanomas.
Results
Distinct activation of signaling cascades because of
mutation in B-RAF and impaired PTEN in LU1205,
but not in FEMX human melanoma cells lines
Analysis of B-RAF mutations in metastatic melanoma
cell lines commonly used in our studies identified
BRAF-activating mutation (T1796A) in LU1205, but
not in FEMX melanoma cells (Figure 1a). Analysis of
the corresponding kinase cascades revealed high basal
levels of active (phosphorylated) forms of MAPK
kinases (ERK and p38), suggesting that they are
constitutively activated in LU1205 but not in FEMX
cells (Figure 1b). In addition, LU1205 cells possessed
very low basal levels of PTEN (Figure 1a and data not
shown). Decreased PTEN expression was reflected in
increased expression and activities of PI3K-AKT
(Figure 1b). LU1205 cells were also found to exhibit
high basal levels of nuclear NF-kB DNA-binding
activity (Figure 1c) and corresponding NF-kB-depen-
dent transcriptional activity (Figure 1d), which could be
attributed to the constitutively active ERK and/or AKT
kinases (Ozes et al., 1999; Jones et al., 2000; Dhawan
and Richmond, 2002). LU1205 cells express relatively
high levels of the Fas receptor (CD95/APO1; Figure 1b),
which could be attributed to high basal levels of NF-kB
(Figure 1c). These findings highlight the major changes
in MAPK/PI3K signaling in the two melanoma cell
lines, as reflected in key targets including NF-kB and
Fas.
STAT3 transcriptional activities are negatively regulated
by ERK
As STATs were shown to be affected by both ERK and
PKB signaling cascades, we elucidated possible changes
in STAT transcriptional activities in melanomas that
could explain the marked differences in the activities of
these signaling cascades.
Analysis of STAT3 phosphorylation in the two
melanoma cell lines that exhibited marked changes
in MAPK/PI3K activities revealed a higher basal
level of Ser 727 phosphorylation in LU1205 cells but
a relatively low level of Tyr 707 phosphorylation,
which is required for STAT3 dimerization-dependent
Figure 1 Differential activation of B-RAF and PI3K downstream
targets in melanoma cells. (a) B-RAF-activating mutations in
human melanomas. (b) Western blot analysis of total cell extracts
(80mg) from FEMX and LU1205 cells using primary antibodies to
ERKs, phospho-ERKs, p38, phosho-p38, PTEN, AKT, phospho-
AKT and Fas. (c) EMSA of nuclear NF-kB DNA-binding activity
of FEMX and LU1205 cells. Two main NF-kB DNA-binding
complexes are indicated; ns, nonspecific band. (d) NF-kB-
dependent transcriptional activity in FEMX and LU1205 cells
was determined after transient transfection of NF-kB-Luc
construct
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nuclear import and transcriptional activities. STAT3
phosphorylation was notably less pronounced in FEMX
cells (Figure 2a). Accordingly, STAT3 exhibited a low
basal level of transcriptional activities, monitored using
the 3xLy6E-Luc reporter construct containing three
GAS elements of the Ly6E gene promoter (Wen et al.,
1995). The analysis to detect STAT3 transcriptional
activities in LU1205 cells revealed a low basal level of
GAS-Luc activities induced upon treatment with
PD98059, the pharmacological inhibitor of MEK-
ERK, (fivefold) in LU1205, but not in FEMX cells
(Figure 2b, c). Exogenous expression of ERK further
decreased the relatively low level of basal GAS-
Luc-dependent activities, while dominant-negative
form of MEK (which suppress ERK activation)
upregulated Gas-Luc. This is similar to what was seen
after treatment with PD98059, although somewhat
less pronounced because of the limited transfection
efficiency of these melanoma cells (Figure 2b, c). These
data suggest that constitutively active ERK signaling
downregulates STAT transcriptional activities in
LU1205 melanoma cells. To further elucidate the
changes in STAT activity after treatment with MEK
inhibitor, we tested the effect of IL6 on GAS-Luc
activities. On its own, IL6 did not alter the activities of
3xLy6E-Luc in either melanoma cell line, further
demonstrating that this signaling cascade is not func-
tional in the melanoma cells studied here. In combina-
tion with PD98059, however, IL6 further increased
Gas-Luc reporter activities in LU1205 cells and induced
such activities in FEMX cells, albeit to a lesser extent
(Figure 2b, c). These results suggest that the signal-
ing pathway required for STAT transcriptional
activities can be activated upon inhibition of the ERK
kinases, albeit to different degrees in each of the
melanoma cell lines.
Treatment with PD98059 markedly increased tyrosine
phosphorylation of STAT3 in LU1205 cells, but not in
Figure 2 Effect of MEK inhibitor PD98059 on STAT3 and STAT5 phosphorylation and STAT-mediated promoter activity. (a, d and
e) Western blotting of total cell extracts from FEMX and LU1205 cells using anti-STAT3, antiphospho-Ser-STAT3, antiphospho-Tyr-
STAT3, anti-STAT5, antiphospho-STAT5, anti-JAK2 and antiphospho-JAK2 Abs. Cells were either untreated or treated with
PD98059 (25mm) or LY294002 as indicated. (b, c) Effect of PD98059 (25 mm) treatment, active ERK and dominant-negative MEK
overexpression on the activity of 3xLy6E-Luc reporter construct in the presence or absence of IL6 (50 ng/ml). 5 105 FEMX or
LU1205 cells were transiently transfected with 0.5 mg of 3xLy6E-Luc reporter construct plus 0.25mg of pCMV-bgal in the presence of
empty vector, ERK or MEK-DN expression vector (0.25 mg). At 16 h after transfection, PD98059 (25mm) and IL6 (50 ng/ml) were
added to the media. After an additional 12 h, luciferase and b-galactosidase activity in the cells was analysed and normalized luciferase
activity was determined
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FEMX cells (Figure 2d and data not shown). Unlike the
changes in tyrosine phosphorylation, there was no
change in the level of Ser phosphorylation on aa 727
(data not shown).
PD98059 treatment also effectively increased tyrosine
phosphorylation of STAT5 in LU1205 cells and to a
lesser degree in FEMX cells (Figure 2e). Given that
ERK is a serine/threonine and not a tyrosine kinase, this
finding suggests that ERK indirectly affects STAT
tyrosine phosphorylation.
Since JAK2 is among the best-characterized
kinases that phosphorylate both STATs on tyrosine
residues, we next assessed changes in JAK phosphoryla-
tion that are expected to directly reflect its activity.
FEMX exhibited basal phosphorylation of JAK2
that was not affected by the pharmacological inhibi-
tors of ERK or PI3K, but treatment of LU1205 cells
with these inhibitors caused a small yet noticeable
increase in JAK2 phosphorylation (Figure 2e).
These findings indicate that ERK may negatively
influence JAK2 phosphorylation and attenuate its
ability to phosphorylate STAT on the respective
tyrosine residues.
As PD98059 was required in both melanoma cell lines
to elicit IL6 effects, we next tested the possibility that
levels of STAT proteins limit GAS-dependent transcrip-
tion. Forced expression of STAT3 alone had a slight
effect on GAS-Luc activities in each melanoma culture.
However, in the presence of PD98059, expression
of exogenous STAT3 resulted in a 40 fold increase
in GAS-Luc activities in LU1205 cells, but not in
FEMX cells (compare Figure 3a, b). These findings
suggest that ERK-mediated inhibition of STAT3
cannot be overcome by overexpression of STAT3, but
excess STAT3 enables stronger GAS-mediated tran-
scription after attenuating ERK-dependent inhibition
with PD98059.
Treatment of LU1205 cells with IL6 caused a twofold
increase in STAT3-induced GAS-Luc activities, but
further increased the degree of activation in PD98059-
treated cells (up to 68-fold; Figure 3a). FEMX subjected
to IL6 treatment exhibited a higher degree of GAS-Luc
activities (up to 10-fold) which was increased (to 27-
fold) upon treatment with PD98059 (Figure 3b). These
results demonstrate that exogenous expression of
STAT3 results in greater GAS-Luc activities in the
FEMX cells and that the amount of STAT3 may, in
part, limit GAS-Luc activities.
In light of the finding that exogenously expressed
STAT3 can induce greater levels of GAS-Luc activities
in FEMX cells than in LU1205 cells, we assessed
whether expression of JAK2 would affect GAS-Luc
activities. Forced expression of JAK2 resulted in less
than a four fold increase in GAS-Luc activity in LU1205
cells, compared with a 15-fold increase in FEMX cells
(Figure 3c). These results indicate that expression of
JAK2 sufficed to rescue inhibition of STAT activities,
albeit to a greater degree in FEMX melanoma cells.
These findings further illustrate that inhibition of JAK-
STAT activities takes place at different levels in LU1205
and FEMX cells.
Figure 3 Effect of MEK inhibitor PD98059 and STAT3 over-
expression on STAT-mediated promoter activity. (a, b) Effect of
STAT3 overexpression, PD98059 (25mm) treatment, on the activity
of 3xLy6E-Luc reporter construct in the presence or absence of IL6
(50 ng/ml). 5 105 FEMX or LU1205 cells were transiently
transfected with 0.5 mg of reporter construct, 0.25mg of pCMV-
bgal plus 0.25mg of STAT3 expression. At 16 h after transfection,
PD98059 (25mm) and IL6 (50 ng/ml) were added to the media.
After an additional 12 h, the cells were analysed for luciferase and
b-galactosidase activity, and normalized luciferase activity was
determined. (c) 5 105 FEMX or LU1205 cells were transiently
transfected with 0.5mg of reporter construct and 0.25mg of pCMV-
bgal in the presence of 0.25mg ERK expression vector, JAK2
expression vector, or both. STAT-dependent reporter activity was
determined as described above
ERK and P13K negatively regulate STAT-transcriptional activities in human cells
M Krasilnikov et al
4095
Oncogene
PI3K elicits negative regulation of GAS-STAT as part of
the MAPK pathway
LU1205 cells not only express mutant B-RAF, but also
low levels of PTEN (Figure 1a). Inhibition of PI3K by
LY appears to have effects on tyrosine phosphorylation
of JAK and STAT5 similar to those seen with PD98059
(Figure 2e). Therefore, we further studied the nature of
the PI3K-MAPK relation in the context of GAS-Luc
activities. Forced expression of a constitutively active
form of p110*, the catalytic subunit of PI3K, increased
total levels of PI3K activities in melanoma cells, while
LY294002 suppressed this increase (Krasilnikov et al.,
1999). Forced expression of p110* did not change basal
transcriptional activities of STAT3, but did efficiently
attenuate the increase in GAS-Luc seen after treatment
with PD98059 (Figure 4a). Overexpression of p85D (a
dominant-negative form of PI3K) upregulated basal
levels of STAT-dependent transcription, close to the
degree reached after expression of MEK-DN
(Figure 4a). These results suggest that like MAPK,
PI3K elicits negative effects on the transcriptional
activities mediated by GAS-Luc promoter sequences.
These results are in agreement with our previous data
(Ivanov et al., 2002) demonstrating that AKT, like
ERK, may serve to limit the degree of STAT-dependent
transcriptional activities. These findings also imply that
PI3K and MAPK converge in their negative regulation
of GAS-Luc activities.
In further addressing relative contributions of PI3K
and MAPK to STAT activities, we tested the effect of
PD98059 and LY294002 both alone and in combination
on each of the two melanoma cultures. Treatment of the
LU1205 cells with LY294002, the pharmacological
inhibitor of PI3K, did not affect basal GAS-Luc
activities, whereas treatment with PD98059 led to a
seven fold increase (Figure 4b). Exogenously expressed
STAT3 led to an additional increase (five fold) in
GAS-Luc transcription proportional to the basal
effect of the corresponding inhibitor (from 2- to 10-fold
Figure 4 Effect of p110* and JAK2 overexpression on STAT-dependent promoter activity. (a) LU1205 cells were transiently
transfected with 0.5 mg of 3xLy6E-Luc reporter construct plus 0.25mg of pCMV-b-gal in the presence of 0.25mg of PI3K p110 or p85 d
together with the empty vector or MEK-DN expression construct (0.25 mg). At 16 h after transfection, the cells were treated with
PD98059, and after an additional 12 h were analysed for luciferase and b-galactosidase activity. (b) LU1205 and FEMX cells were
transiently transfected with 0.5mg of 3xLy6E-Luc reporter construct plus 0.25mg of pCMV-b-gal in the presence or absence of 0.25mg
of STAT3 expression construct. At 16 h after transfection, the cells were treated with PD98059, LY294002 or their combination, and
after an additional 12 h cells were analysed for luciferase and b-galactosidase activity. (c) Activity of 3xLy6E-Luc reporter construct
was analysed after cotransfection with PTEN, p110 and JAK2 expression vectors. Treatment of the cells with PD989059 was
performed under the same conditions as above. (d) FEMX and LU1205 cells were treated with 50 mm LY294002 1 h before irradiation
with UVC (60 J/m2) in the presence of normal mouse IgG, anti-FasL mAb (2mg/ml) or anti-TNFa mAb (2 mg/ml). Apoptosis levels
were determined after an additional 16 h using PI staining and flow cytometry
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in LY-treated, and from 8- to 34-fold in PD98059-
treated cells; Figure 4b). These results suggest that PI3K
and MAPK operate on the same signaling pathway for
activation of STAT-GAS activities. These observations
also imply that MAPK is upstream of PI3K in this
pathway, as it is capable of eliciting a greater effect on
GAS-Luc activities. The latter conclusion is supported
by the findings that p110 can attenuate PD98059 effects
(Figure 4a), and that the combination of the two
inhibitors does not result in additive or synergistic
effects on GAS-Luc transcription (Figure 4b). Further-
more, forced expression of JAK2 sufficiently induces
GAS-Luc activities in a manner that can be further
increased upon the expression of PTEN, with effects
similar to that of PD98059 (Figure 4c). Similar to
activities observed in cells transfected with STAT3
(Figure 4b), the combination of LY294002 and
PD98059 did not cause any additional increase in
JAK2-mediated activation of GAS-Luc activities
(Figure 4c). Together, these results suggest that con-
stitutively high activities of ERK and PI3K-AKT in
LU1205 cells inhibit STAT-transcriptional activities via
their effects on JAK2. Neither treatment affected GAS-
Luc activities in FEMX cells (Figure 4b), pointing to the
role of impaired PTEN and MAPK signaling in LU1205
cells and suggesting that other mechanism(s) contribute
to the regulation of STAT in FEMX cells.
Combined inhibition of PI3K and MAPK supersensitizes
LU1205 and FEMX melanoma cells to apoptosis via
distinct death cascades
As STAT3-GAS activities are inhibited, either PI3K or
by MAPK, the level of FAS expression should increase
because STAT3 is required for silencing the FAS
promoter. Indeed, FAS expression was substantially
higher in LU1205 cells, compared to the expression in
FEMX cells (Figure 1b). Inhibition of PI3K or MAPK
was expected to relieve STAT suppression and to result
in decreased FAS surface expression, and this was
observed in LU1205 cells, but not in FEMX cells (data
not shown). However, treatment of LU1205 cells with
LY294002 resulted in a marked increase in the degree of
apoptosis after UV treatment (Figure 4d) because of
upregulation of FasL levels (not shown). The sensitiza-
tion of LU1205 to UV-induced apoptosis by LY294002
treatment could be attenuated by antibodies antagonis-
tic to FasL but not to TNFa (Figure 4d). As occurred
with LU1205 cells, treatment of FEMX cells with
LY294002 resulted in their sensitization to apoptosis,
albeit to a lower degree, and via the TNFa-TNFR1-
mediated pathway rather than the FAS death cascade
(Figure 4d).
Whereas treatment of LU1205 cells with PD98059
resulted in about 8% apoptosis (without any other
stimuli), the combination of LY294002 and PD98059
caused a marked degree of apoptosis (46%) that could
be attenuated by antibodies to TRAIL (Figure 5a).
Similarly, combined treatment with PD and LY
markedly increased the sensitization of FEMX cells to
apoptosis (68%), primarily driven by the TNFa path-
way, as revealed in the ability of antagonistic antibodies
(to TNFa, but not to FasL or TRAIL) to attenuate this
response (Figure 5b). These findings suggest that despite
the marked difference among the two melanoma
cultures in their responses to PI3K, MAPK and STAT
activities, both are sensitized to apoptosis to a marked
degree after exposure to a combination of the two
inhibitors, albeit via alternate death cascade pathways.
These findings indicate that MAPK and PI3K affect
additional yet distinct targets in the two melanomas
studied here, which are of critical importance in their
sensitization to apoptosis.
Discussion
Recent advances in the understanding of genetic
changes underlying melanoma development suggest
that MAPK signaling is affected in over 80% of human
melanomas as a result of mutation in either the Ras
or the B-RAF genes, resulting in a constitutively high
activity of corresponding MAPK, including ERKs.
Here we demonstrate that constitutively high ERK
activity suppresses the JAK-STAT signaling cascade.
We further demonstrate that, like ERK, PI3K also
elicits negative effects on JAK-STAT signaling. Our
findings suggest that PI3K utilizes the same signaling
cascade as ERK and may be affected by ERK, as p110
efficiently overrides the effect of the MEK-ERK
inhibitor PD98059 (Figure 6). Inhibition of STAT
transcriptional activities was associated with a decrease
in its tyrosine phosphorylation, which could be rescued
with treatment using the pharmacological inhibitor of
MEK. Further, our data suggest that inhibition of
STAT tyrosine phosphorylation is because of inhibition
of JAK activities, as inhibitors of MAPK increased the
level of JAK phosphorylation and, concomitantly,
phosphorylation on STAT. Our results are in agree-
ment with the finding of Sengupta et al. (1998),
demonstrating a decrease in IL6 signaling and STAT3
activation by MAPK-ERK in human myeloma cells,
thereby providing additional support for the notion
that ERK can elicit inhibition rather than activation of
the STAT signaling cascade. The ability of ERK to
inhibit STAT signaling was also demonstrated in other
studies (Kim and Baumann, 1999). Nevertheless, the
present work adds the following important insights into
our understanding of ERK-dependent inhibition of
STAT: (a) our study demonstrates ERK inhibition of
STAT in the physiological context of melanoma with a
mutant B-RAF gene, thereby highlighting the conse-
quences of this prevalent mutation for STAT activities;
(b) our data suggest that ERK inhibition of STAT is
mediated via targeting of JAK; (c) our results position
PI3K as one of the components within the MAPK
cascade, as p110 can override activation of STAT by
PD98059.
The finding that ERK inhibits STAT via its down-
regulation of JAK raises several interesting questions.
The first question relates to the mechanisms underlying
the inhibition of JAK by ERK. Our experiments
ERK and P13K negatively regulate STAT-transcriptional activities in human cells
M Krasilnikov et al
4097
Oncogene
indicate that it is likely that ERK indirectly regulates the
degree of JAK activity, although we cannot rule out
effects on another kinase that may phosphorylate
STAT3 on tyrosines. Associated inhibitors, SOCS
(Cacalano et al., 2001), and associated phosphatase,
CD45 (Irie-Sasaki et al., 2001), are among the possible
candidates for affecting JAK activity by MAPK
phosphorylation. Further studies will determine the
target of the ERK activity that elicits inhibition of JAK
and results in suppression of STAT3 activity.
Figure 5 LY294002 and PD98002 inhibitors induce apoptosis of melanoma cells. (a, b) Effect of pretreatment with anti-TRAIL and
anti-TNFa (2mg/ml) Abs on LY294002 (50mm), PD98002 (50mm) or (LY294002þPD98002)-induced apoptosis of LU1205 and
FEMX cells. Apoptosis levels were determined 48 h after treatment using PI staining and flow cytometry
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Inhibition of STAT activities coincides with an
increased expression of Fas receptor, which is otherwise
suppressed by the cooperation between STAT3 and
c-Jun. Increased cell surface expression of Fas in
LU1205 cells is expected to result in sensitization of
the cells to Fas-mediated apoptosis. Owing to the low
basal levels of endogenous FasL in these cells, such
sensitization does take place after UV irradiation or
upon addition of exogenous FasL. Nevertheless, it is
expected that other targets downstream of the Fas death
cascade would be impaired by high levels of MAPK/
PI3K (Panka et al., 2001). LU1205 cells also possess
high basal levels of p38 activity, which could also
contribute to antiapoptotic signaling by p38 effect on
NF-kB activity (Ivanov and Ronai, 2000). Clearly,
inhibition of the ERK cascade had a limited effect on
LU1205 or FEMX cells to spontaneous apoptosis.
Further, inhibition of ERK signaling by the pharmaco-
logical inhibitor appears to sensitize LU1205 to sponta-
neous apoptosis via the TRAIL–TRAIL-R cascade,
whereas the FEMX cells are sensitized via the TNFa-
mediated pathway. This observation suggests that
different changes in the signaling cascades occur in the
two tumors and affect alternate death signaling cas-
cades. LU1205 cells exhibit mutation in B-RAF and
aberrant PTEN expression, yet, FEMX cells exhibit
equal resistance to treatment as a result of changes that
have yet to be identified. Nevertheless, in both cases,
inhibition of MAPK alone has a limited effect, but
inhibition of both the PI3K and the ERK cascades
resulted in supersensitization of both melanoma cultures
to apoptosis, albeit via alternate death pathways. Such
sensitization clearly involved targets distinct in each of
the two melanoma cell lines studied here and not
involved in the common effect of the two inhibitors on
JAK-STAT signaling. These observations imply that
melanomas lacking B-Raf or Ras mutation may
experience other changes that are either part of or
affected by PI3K and MAPK, as found in the FEMX
cells. Our conclusion is in agreement with studies
performed on other tumor types that clearly implicate
the role of the RAS-RAF-MEK-ERK pathway in
tumor resistance to apoptosis, in part via the activation
of the hepatocyte growth factor or PI3K signaling (von
Gise et al., 2001; Edwards et al., 2002; Paumelle et al.,
2002). As reported in the present study (see model in
Figure 6), the roles of PI3K and B-RAF in STAT
signaling suppression are part of a complex network of
signaling cascades that converge and acquire melanoma
resistance, but could be overcome after inhibition of
both PI3K and MAPK pathways, resulting in super-
sensitization of these tumors to apoptosis.
Materials and methods
Cell culture
Human melanoma FEMX cells were maintained in RPMI
medium supplemented with 10% fetal bovine serum (FBS),
l-glutamine and antibiotics. LU1205 cells were maintained
in MCDB153/L15 medium (4 : 1) supplemented with FBS,
l-glutamine and antibiotics. Cells were grown at 37oC with
5% CO2.
Transient transfection and luciferase assay
The luciferase reporter gene containing three GAS elements
from the Ly6E gene promoter was previously described (Wen
et al., 1995). Transient cotransfection of luciferase reporter
gene together with different expression constructs (for STAT3,
STAT3–phosphomutant, JAK2, PTEN, and the p110 subunit
of PI3K and pCMV-bgal) into the cells was performed using
Lipofectamine (Life Technology-BRL). 16 h after transfection,
cells were treated with inhibitors. Luciferase activity was
determined after an additional 12 h using the Luciferase
assay system (Promega, USA) and normalized on the basis
of b-galactosidase level in transfected cells. The active form of
ERK and dominant-negative form of MEK (MEK-A) in
pcDNA3 vector, active and dominant-negative forms of PI3K,
p110* and p85D, respectively, were kindly provided by Dr
Andrew Chan and used for cotransfection with the reporter
3Ly6-Luc construct. MAPK inhibitor PD98059 (Calbio-
chem) was used at final concentrations of 25–50mm. PI3K
inhibitor LY294002 was used at a final concentration 50 mm.
Apoptosis analysis
Cells were exposed to UVC at 60 J/m2 and treated with MAPK
inhibitor PD98059 (25 mm) or PI3K inhibitor LY294002
(50 mm), and apoptosis levels were detected after 16–48 h by
quantifying the percentage of hypodiploid nuclei undergoing
DNA fragmentation to the left of the diploid G0/1 peak. Flow-
cytometric analysis was performed on a FACS Calibur flow
Figure 6 Chart outlines the signaling cascades that are modified in
the course of melanoma development and their effect on STAT
signaling and the sensitization of melanoma to apoptosis.
Constitutively active MEK and downstream kinases, including
ERK, elicit suppression of JAK-STAT transcriptional activities,
congruent with suppression that is elicited by the PI3K pathway.
Suppression is likely to converge the two signaling pathways either
at the level of the actual kinases or their target (JAK or upstream
component), as indicated by question marks. Suppression of
STAT3 can be alleviated with the use of either dominant-negative
kinases or their corresponding pharmacological inhibitors as
indicated. Combination of these inhibitors also results in synergis-
tic sensitization of the melanomas to apoptosis, probably becasue
of the effect on multiple targets, illustrated in figure, in addition to
the effects shown here for STAT
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cytometer (Becton Dickinson) using the CellQuest program.
Cell cultures were pretreated with Abs antagonistic to FasL,
TNFa or TRAIL (2 mg/ml) in some experiments.
Western blot analysis
The cells were lysed in buffer containing 50mm Tris-HCl, pH
7.5, 0.5% NP-40, 150mm NaCl, 1mm EDTA, 1mm DTT,
1mm PMSF, 0.1mm Na-orthovanadate and aprotinin (10 mg/
ml). Cell lysates (100mg protein) were resolved on 10% SDS–
PAGE, transferred to a nitrocellulose membrane and pro-
cessed according to standard methods. Primary antibodies
(Abs) to phosphorylated and nonphosphorylated STAT3, p38
and ERKs, control Ab to AKT and Phospho-AKT (Ser473)
Ab, and PTEN Ab were obtained from Cell Signaling
(Beverly, MA, USA). Anti-JAK2 and anti-Phospho-JAK2
(Tyr1007, Tyr1008) Abs were obtained from Upstate Biotech-
nology (Lake Placid, NY, USA). Anti-Fas Ab from Pharmin-
gen (San Diego, CA, USA) was also used. Anti-rabbit
IgG conjugated to horseradish peroxidase were used as
secondary antibodies. Signals were detected by ECL reagent
(Amersham).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed for the determination of NF-kB DNA
binding activity as previously described (Ivanov et al., 1995).
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